SCIG Hizentra denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Uses Step Therapy for Hizentra

Aetna's step-therapy protocol for immunoglobulin products typically requires that a patient first demonstrate a trial of a preferred IVIG product or a lower-cost SCIG formulation before Hizentra is authorized. A step-therapy denial means Aetna does not have documented evidence that the required prior therapy was tried, was inadequate, or was contraindicated for this patient. This is a process-based denial — the clinical need for immunoglobulin replacement is not being disputed, but the specific product choice is.

## Why This Denial Is Appealable

Step-therapy protocols must include a meaningful exception process, and many states have enacted step-therapy reform laws that give patients and prescribers the right to bypass mandatory steps when clinically justified. Even absent a state law, Aetna's criteria must allow exceptions when the required step is clinically inappropriate, has already failed, or would cause harm. If the patient has a documented reason to skip the required step, the denial is appealable.

## Federal Appeal Framework

• Step-therapy exception request: File this first — it directly targets the step-therapy barrier and can be faster than a full appeal. Grounds include prior treatment failure, clinical contraindication to the required step, or a prescriber determination that the step would be harmful.
• Internal appeal: If the exception is denied, escalate to a formal internal appeal within your plan's deadline.
• External review (ACA §2719 / ERISA §503): After exhausting internal options, request IRO review within 4 months. The IRO assesses whether the step-therapy requirement is clinically appropriate as applied to this patient.
• State step-therapy laws: Check whether your state has enacted step-therapy protection legislation — many states require insurers to grant exceptions under specific circumstances.

## Documentation to Gather

1. Prior therapy history — dated records of any previous IVIG or alternative SCIG product, including the product name, duration of treatment, clinical response, and reason for discontinuation or change. 2. Adverse reaction or intolerance records — if the required step product caused or is likely to cause adverse effects, document this with clinical notes. 3. Route and tolerability rationale — if subcutaneous administration via Hizentra specifically is required (e.g., tolerability of subcutaneous vs. IV, venous access limitations, home infusion safety), document this in the prescriber letter. 4. Clinical urgency documentation — if delaying treatment to complete a step-therapy trial would cause clinical harm, document that risk explicitly. 5. Prescriber exception letter — a detailed letter addressing each step-therapy exception criterion in Aetna's policy.

## Criteria-Mapping Strategy

Obtain Aetna's published step-therapy criteria for this drug class. For each required step, document either: (a) the completed trial with outcome, or (b) the specific clinical reason the step is not appropriate for this patient. Reference the FDA-approved prescribing information for Hizentra where it supports individualized product selection. Submit a structured, criterion-by-criterion response.